Browsing Tag
neuropsychiatry
2 posts
Is bretisilocin the Cymbalta of psychedelic‑inspired psychiatry? What AbbVie’s $1.2 bn bet reveals
AbbVie’s $1.2 B deal for bretisilocin could signal the next era of antidepressants. Could this short‑acting compound become the Cymbalta of psychedelic‑inspired psychiatry?
After AbbVie took bretisilocin, what’s next for Gilgamesh Pharma’s neuropsychiatric pipeline?
Gilgamesh Pharma, newly spun out from the AbbVie deal, holds a promising psychiatric drug pipeline. Here's what the industry should expect next.